Avid Bioservices Inc (CDMO)

[cjgaddy]

3-5-13: Piper Jaffray initiates PPHM, Overweight, PT=$2.50

3-5-13 4:34pmET: “Piper Jaffray initiates coverage on Peregrine Pharmaceuticals (NASDAQ: PPHM) with a Overweight, PT $2.50”
StreetInsider link => http://tinyurl.com/ba4soh9

3-6-13/Benzinga: “Piper Jaffray Initiates Peregrine Pharmaceuticals with Overweight on Attractive Risk-Reward Opportunities”
By Dwight Einhorn, Benzinga Staff Writer
In a report published Tuesday, Piper Jaffray initiated coverage on Peregrine Pharmaceuticals (PPHM) with an Overweight rating and $2.50 price target.
Piper Jaffray noted:
“Peregrine is advancing 2 novel cancer drug candidates that, combined with its hybrid business model, present attractive risk-reward opportunities in our view. Lead candidate bavituximab (bavi) has recently endured negative news flow, increasing skepticism from investors but creating a potential buying opportunity, in our view. Bavi has broad potential due to its novel mechanism of action, providing many shots on goal for potentially large oncology markets like non-small cell lung cancer (NSCLC, ~$10bn+ market) and pancreatic cancer (PC), with multiple data-driven & regulatory catalysts in 2013. A 2nd major therapeutic candidate, Cotara, is a high risk but potentially high-return targeted radiopharmaceutical for brain cancer that we believe Peregrine will partner prior to starting a Phase III trial late in ‘13.”
PPHM closed on Tuesday at $1.31.
http://www.benzinga.com/analyst-ratings/analyst-color/13/03/3394234/update-piper-jaffray-initiates-peregrine-pharmaceuticals

=> Per RRDog iHub 115066/83, PJ report also said, “Bavi Controversy unfairly weighing on shares in our view… In addition, we believe the size & fully-human nature may support PGN650’s utility as a 2nd-gen “bavi-better.” Phase I data for PGN650 is expected this year, and this may result in the company becoming an acquisition candidate, vs. simply a partnering candidate, based on broad applicability but also long run-way potential for the emerging PS-targeting franchise."

- - - - - - - - - - -
3-5-13: Charles Duncan, PhD, Piper Jaffray added to Peregrine’s “Analyst Coverage” webpage – not sure when he was added, but very recently for sure…
http://ir.peregrineinc.com/analysts.cfm
Firm. . .Analyst
• JMP Securities - Jason N. Butler, Ph.D
• McNicoll, Lewis & Vlak - George B. Zavoico, Ph.D.
• Piper Jaffray - Charles Duncan, PhD
• ROTH Capital Partners - Joseph Pantginis, Ph.D.

= = = = = = = = = = = = = =
Charles Duncan, PhD
Sr. Research Analyst – Universe “Emerging BioPharma”
Charles Duncan, Ph.D., joined Piper Jaffray in 2012 as a managing director and senior research analyst focused on small- and mid-cap emerging growth biotechnology companies. Duncan brings more than 17 years of sell-side experience during which he has covered a broad range of biopharma companies, most recently serving as an analyst at JMP Securities since 2002. Previously, Duncan covered the sector at Dresdner Kleinwort Wasserstein, Vector Healthcare Group - Prudential Securities, Tucker Anthony Cleary Gull and Chatfield Dean & Co. Duncan has been recognized by industry sources, including the Financial Times and StarMine Analyst Awards, as being among the best analysts for his fundamental and timely analysis. Duncan began his career as a manager of clinical development at Global Drug Dev., Inc., a pharmaceutical development consulting firm, and he also launched InfusionVision Medical, a venture-backed start-up medical device company. He is a graduate of the Univ. of Wisconsin-Madison and holds a doctorate in pharmaceutical sciences with a concentration in neuropharmacology from the Univ. of Colorado.
http://www.piperjaffray.com/2col.aspx?id=7&analystid=1275&title=Analyst%20Information%20for%20Charles%20Duncan,%20PhD


= = = = = = = = = = = = = = = = = = = = =
Excerpts+Slides from CEO S.King’s 3-5-13 COWEN Talk (Boston)
Mar4-6 2013: “Cowen’s 33rd Annual Health Care Conf.”, Boston
CEO Steven King’s 24 min. Presentation – Cowen/Boston
=> http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85315415